论文部分内容阅读
目的探讨雄激素受体(AR)和Stathmin在三阴性乳腺癌患者中的表达情况并分析此与临床病理因素的相关性。方法回顾性收集2005～2009年期间在四川省人民医院乳腺外科确诊为三阴性乳腺癌并符合纳入条件患者共83例。使用免疫组织化学EnVision二步法检测AR和Stathmin蛋白在三阴性乳腺癌中的表达情况。用Spearman检验分析AR和Stathmin表达与患者年龄、肿瘤大小、淋巴结状态及病理分级的相关性。结果 AR和Stathmin在三阴性乳腺癌组织中表达阳性率分别为37.3%(31/83)和98.8%(82/83)。AR的表达与年龄呈正相关(rs=0.302,P=0.006),与肿瘤病理分级也呈正相关(rs=0.225,P=0.041),而与肿瘤大小和淋巴结状态无关(P>0.05)。Stathmin的表达与患者年龄、肿瘤大小、淋巴结状态及病理分级均无关(P>0.05)。结论 AR表达与乳腺癌患者的年龄及肿瘤分级有关,而Stathmin与生物学行为无关,其作为三阴性乳腺癌预后判断指标还需要进一步研究。
Objective To investigate the expression of androgen receptor (AR) and Stathmin in triple-negative breast cancer patients and to analyze the correlation with clinicopathological factors. Methods A total of 83 patients with triple negative breast cancer diagnosed as breast cancer from Department of Breast Surgery, People’s Hospital of Sichuan Province from 2005 to 2009 were enrolled in this study. Immunohistochemistry EnVision two-step method was used to detect the expression of AR and Stathmin in triple negative breast cancer. Spearman test was used to analyze the correlation between AR and Stathmin expression and patient’s age, tumor size, lymph node status and pathological grade. Results The positive rates of AR and Stathmin in triple negative breast cancer tissues were 37.3% (31/83) and 98.8% (82/83), respectively. The expression of AR was positively correlated with age (rs = 0.302, P = 0.006), and also positively correlated with tumor grade (rs = 0.225, P = 0.041), but not with tumor size and lymph node status (P> 0.05). The expression of Stathmin had no correlation with patient age, tumor size, lymph node status and pathological grade (P> 0.05). Conclusion The expression of AR is related to the age and tumor grade of breast cancer patients. Stathmin has nothing to do with the biological behavior. As a prognostic indicator of triple negative breast cancer, further study is needed.